Tian Yaji, New David C, Yung Lisa Y, Allen Rodger A, Slocombe Patrick M, Twomey Breda M, Lee Maggie M K, Wong Yung H
Department of Biochemistry, The Molecular Neuroscience Center, and The Biotechnology Research Institute, Hong Kong University of Science and Technology, Kowloon, Hong Kong, China.
Celltech R & D, Slough, GB.
Eur J Immunol. 2004 Mar;34(3):785-795. doi: 10.1002/eji.200324166.
Chemokines regulate the chemotaxis, development, and differentiation of many cell types enabling the regulation of routine immunosurveillance and immunological adaptation. CC chemokine receptor 1 (CCR1) is the target of 11 chemokines. This promiscuity of receptor-ligand interactions and the potential for functional redundancy has led us to investigate the selective activation of CCR1-coupled pathways by known CCR1 agonists. Chemokines leukotactin-1, macrophage inflammatory protein (MIP)-1alpha, monocyte chemotactic peptide (MCP)-3, RANTES, and MIP-1delta all inhibited adenylyl cyclase activity in cells transiently transfected with CCR1. In contrast, only MIP-1delta was unable to signal via G14-, G16- or chimeric 16z44-coupled pathways. In a stable cell line expressing CCR1 and Galpha14, all of these five chemokines along with hemofiltrate CC chemokine (HCC)-1 and myeloid progenitor inhibitory factor (MPIF)-1 were able to stimulate G(i/o)-coupled pathways, but MIP-1delta, HCC-1 and MPIF-1 were unable to activate G14-mediated stimulation of phospholipase Cbeta activity. In addition, MIP-1delta was unable to promote the phosphorylation of extracellular signal-regulated kinase and c-Jun N-terminal kinase. This suggests that different chemokines are able to selectively activate CCR1-coupled pathways, probably because of different intrinsic ligand efficacies. CCR1 and Galpha14 or Galpha16 are co-expressed in several cell types and we hypothesize that selective activation of chemokine receptors provides a mechanism by which chemokines are able to fine-tune intracellular signaling pathways.
趋化因子调节多种细胞类型的趋化性、发育和分化,从而实现对常规免疫监视和免疫适应的调节。CC趋化因子受体1(CCR1)是11种趋化因子的靶点。这种受体-配体相互作用的混杂性以及功能冗余的可能性,促使我们研究已知的CCR1激动剂对CCR1偶联途径的选择性激活。趋化因子白细胞趋化素-1、巨噬细胞炎性蛋白(MIP)-1α、单核细胞趋化肽(MCP)-3、调节激活正常T细胞表达和分泌因子(RANTES)以及MIP-1δ,均能抑制瞬时转染CCR1的细胞中的腺苷酸环化酶活性。相比之下,只有MIP-1δ无法通过G14-、G16-或嵌合16z44偶联途径发出信号。在表达CCR1和Gα14的稳定细胞系中,这五种趋化因子以及血液滤过CC趋化因子(HCC)-1和髓系祖细胞抑制因子(MPIF)-1均能刺激G(i/o)偶联途径,但MIP-1δ、HCC-1和MPIF-1无法激活G14介导的磷脂酶Cβ活性刺激。此外,MIP-1δ无法促进细胞外信号调节激酶和c-Jun氨基末端激酶的磷酸化。这表明不同的趋化因子能够选择性激活CCR1偶联途径,可能是由于不同的内在配体效能。CCR1和Gα14或Gα16在几种细胞类型中共同表达,我们推测趋化因子受体的选择性激活提供了一种机制,通过该机制趋化因子能够微调细胞内信号通路。